Q-omics provides the consensus-scored SSTR4 profile across patient tissues and cancer cell-line models. SSTR4 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SSTR4 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, SSTR4 RNA expression shows 9,316 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, and THYM as cancer lineages where SSTR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSTR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSTR4 survival associations across molecular data types. SSTR4 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSTR4 RNA expression–survival associations across cancer types. High SSTR4 expression shows unfavorable associations in BLCA, ACC, ESCA and LIHC, but favorable associations in LUAD and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for SSTR4 RNA expression.
This table summarizes SSTR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SSTR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSTR4 shows lower tumor expression in LUAD, THCA, LUSC, COAD, KIRC and STAD. The LUAD box plot shows higher SSTR4 RNA expression in normal versus tumor tissue (log2 FC = −0.373, t-test p < 0.001).
This table shows molecular features associated with SSTR4 in patient tissues and cancer cell lines. In patient samples, SSTR4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SSTR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
